Ozempic vs. Metformin: Which Diabetes Drug Is Right for You?

Two of the most talked-about medications for type 2 diabetes are metformin and Ozempic (semaglutide). They could not be more different: metformin is a 60-year-old generic pill that costs $4 a month, while Ozempic is a weekly injection that costs over $900 a month without insurance. Yet both are highly effective at lowering blood sugar, and both are recommended by major diabetes guidelines.

So how do you know which one is right for you? This deep-dive comparison covers everything you need to know — mechanism, efficacy, side effects, cost, and the clinical guidelines that help doctors decide.

At a Glance

How Each Drug Works

Metformin

Metformin works primarily by reducing the amount of glucose the liver produces and releases into the bloodstream. The liver is responsible for producing glucose overnight (hepatic glucose production), and in type 2 diabetes this process is dysregulated — the liver keeps producing glucose even when blood sugar is already elevated. Metformin suppresses this overproduction.

Metformin also improves insulin sensitivity in muscle tissue, helping cells take up glucose more efficiently. It has a mild effect on slowing intestinal glucose absorption as well. Importantly, metformin does not stimulate insulin secretion, which is why it carries virtually no risk of hypoglycemia.

For a complete overview of metformin, see our Metformin Explained guide.

Ozempic (Semaglutide)

Semaglutide (Ozempic) is a GLP-1 receptor agonist — a synthetic version of the gut hormone GLP-1 that has been engineered to last in the body for a week rather than minutes. It works through multiple mechanisms simultaneously:

• Stimulates insulin secretion in a glucose-dependent manner (only when blood sugar is elevated)
• Suppresses glucagon, the hormone that signals the liver to release glucose
• Slows gastric emptying, reducing the rate at which food-derived glucose enters the bloodstream
• Acts on the brain to reduce appetite and food intake

The combination of these effects makes semaglutide one of the most potent blood sugar-lowering agents available, with the added benefit of significant weight loss.

Efficacy Comparison

Blood Sugar Lowering (A1c Reduction)

Both drugs are effective at lowering A1c, but Ozempic is more potent:

• Metformin: Reduces A1c by 1.0–1.5 percentage points on average
• Ozempic (0.5 mg/week): Reduces A1c by approximately 1.5 percentage points
• Ozempic (1.0 mg/week): Reduces A1c by approximately 1.8–2.0 percentage points

In the SUSTAIN-7 trial, semaglutide 1.0 mg reduced A1c by 1.8% compared to 1.4% for dulaglutide 1.5 mg. Head-to-head data against metformin specifically is limited, but indirect comparisons consistently show semaglutide as the more potent agent.

Weight Loss

This is where the two drugs diverge most dramatically:

• Metformin: Weight-neutral to modest weight loss (0.5–1.5 kg over 6 months)
• Ozempic: Significant weight loss (4–6 kg at diabetes doses; up to 15 kg at the higher Wegovy dose)

For patients with obesity and type 2 diabetes, the weight loss benefit of Ozempic is clinically meaningful — excess weight worsens insulin resistance, and losing 5–10% of body weight can meaningfully improve blood sugar control independent of the drug's direct effects.

Side Effects

Metformin Side Effects

The most common side effects of metformin are gastrointestinal: nausea, diarrhea, stomach cramps, and a metallic taste. These affect 20–30% of patients, particularly when starting the medication or increasing the dose. Most patients find that taking metformin with food and starting at a low dose (500 mg once daily) significantly reduces these effects. Extended-release metformin (Glucophage XR) also tends to cause fewer GI side effects than immediate-release.

A rare but serious risk is lactic acidosis — a dangerous buildup of lactic acid in the blood. This risk is very low in patients with normal kidney function but increases significantly in patients with severe kidney disease, liver disease, or conditions that reduce tissue oxygen delivery (such as heart failure or sepsis). Metformin should be held before contrast dye procedures and in patients who are acutely ill.

For a complete side effect guide, see our Metformin Side Effects article.

Ozempic Side Effects

The most common side effects of Ozempic are also gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are most pronounced when starting the medication and typically improve over 4–8 weeks as the body adjusts. The weekly injection schedule and slow dose titration (starting at 0.25 mg/week for 4 weeks before increasing to 0.5 mg/week) are designed to minimize these effects.

More serious but rare risks include:

• Pancreatitis — patients should seek medical attention for severe abdominal pain
• Diabetic retinopathy worsening — rapid A1c reduction can temporarily worsen retinopathy; ophthalmology monitoring is recommended
• Thyroid C-cell tumors — seen in rodent studies; Ozempic carries a black box warning, though human relevance is uncertain
• Injection site reactions — mild redness or nodules at the injection site

Cost and Affordability

The cost difference between these two medications is stark:

Metformin is one of the most affordable medications in the world. It is available as a generic for $4–$15 per month at most pharmacies and is on the $4 generic list at Walmart, Costco, and many other chains.

Ozempic is one of the most expensive diabetes medications. Without insurance, a monthly supply costs approximately $900–$1,000. However, Novo Nordisk offers a savings card program that can reduce the cost to $25/month for eligible commercially insured patients. Medicare Part D covers Ozempic for diabetes (but not for weight loss), though coverage varies by plan.

Who Should Start with Metformin?

Current guidelines from the American Diabetes Association (ADA) and the American Association of Clinical Endocrinology (AACE) both recommend metformin as the preferred first-line medication for most patients with type 2 diabetes. The reasons are compelling:

• It is highly effective (1.0–1.5% A1c reduction)
• It has an excellent safety record spanning 60 years
• It costs $4–$15 per month
• It has a low hypoglycemia risk
• It has some evidence for cardiovascular benefit (UKPDS trial)
• It can be combined with virtually any other diabetes medication

Metformin is the right starting point for most newly diagnosed patients with type 2 diabetes who have an A1c below 9% and no compelling indication for a GLP-1 agonist.

Who Might Go Directly to Ozempic (or Another GLP-1)?

The 2023 ADA Standards of Care introduced an important shift: for patients with established cardiovascular disease, heart failure, or chronic kidney disease, GLP-1 receptor agonists with proven cardiovascular benefit (including semaglutide) are now recommended as first-line or early add-on therapy, regardless of A1c level.

Ozempic may be the better first choice for patients who:

• Have established cardiovascular disease — the SUSTAIN-6 trial showed semaglutide reduced major adverse cardiovascular events by 26%
• Have significant obesity — the 4–6 kg weight loss at diabetes doses (and up to 15 kg at Wegovy doses) is clinically meaningful for patients with obesity
• Have an A1c above 9–10% — at very high A1c levels, the greater potency of GLP-1 agonists may be needed to reach target
• Are already on metformin and need additional control — adding Ozempic to metformin is one of the most effective combination regimens available

Can You Take Both?

Yes — and this is actually one of the most effective combinations in type 2 diabetes management. Metformin and semaglutide work through completely different mechanisms, so they complement each other well. Metformin reduces hepatic glucose production and improves insulin sensitivity, while semaglutide stimulates insulin secretion, suppresses glucagon, and reduces appetite.

Most patients who start on metformin and need additional blood sugar control will eventually add a second agent. Given the cardiovascular and weight loss benefits of GLP-1 agonists, adding semaglutide to metformin is a common and well-supported approach.

For a direct head-to-head comparison page, see our Metformin vs. Semaglutide comparison.

Key Takeaways

Metformin and Ozempic are both excellent diabetes medications, but they serve different roles. Metformin is the right starting point for most patients — it is safe, affordable, and effective. Ozempic is a more powerful option with additional cardiovascular and weight loss benefits, but it comes at a dramatically higher cost and requires weekly injections.

The choice between them should be guided by your A1c level, cardiovascular risk, weight, kidney function, insurance coverage, and personal preferences. For many patients, the answer is not either/or — it is both, used together as a highly effective combination regimen.

This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication.